Silver Book Fact

For beneficiaries with wet age-related macular degeneration (AMD), annual Medicare part B payments for vision care increased from $1,504 per beneficiary in 1994 to $3,263 in 2006–due in large part to anti-VEGF treatments.

Day, Shelley, Kofi Acquah, Paul P. Lee, Prithvi Mruthyunjaya, and Frank A. Sloan. Medicare Costs for Neovascular Age-Related Macular Degeneration, 1994-2007. Ophthalmol. May 2011; 152(6): 1014-20. http://www.ajo.com/article/S0002-9394%2811%2900410-7/abstract

Reference

Title
Medicare Costs for Neovascular Age-Related Macular Degeneration, 1994-2007
Publication
Ophthalmol
Publication Date
May 2011
Authors
Day, Shelley, Kofi Acquah, Paul P. Lee, Prithvi Mruthyunjaya, and Frank A. Sloan
Volume & Issue
Volume 152, Issue 6
Pages
1014-20
URL
Read Full Resource

Categories

  • Cost of Disease
  • Economic Burden

Related Facts

  • Of the study participants in the Los Angeles Latino Eye Study (LALES) who had open-angle glaucoma, 75% were previously undiagnosed.  
  • One-third of age-related macular degeneration (AMD) patients suffer from clinical depression.  
  • The average cost in 2004 per glaucoma patient age 40 to 64 using medications and vitamins was $806.  
  • In one study of patients age 48 and older, 17% of the women and 11.1% of the men had dry eye.  
  • An estimated 1 million Americans over the age of 40 are legally blind.